EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis

Vincent Joustra, Andrew Y F Li Yim, Sara van Gennep, Ishtu Hageman, Tristan de Waard, Evgeni Levin, Peter Lauffer iD, Wouter de Jonge, Peter Henneman, Mark Löwenberg, Geert D'Haens

Journal of Crohn's and Colitis · 14.08.2024 · 18 (8) · 1179-1189

DOI: 10.1093/ecco-jcc/jjad129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 01.08.2023. Verfasst von Vincent Joustra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Piperidines, Colitis, Ulcerative, DNA Methylation, Pyrimidines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helmsley Foundation, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Predictive biomarkers for treatment efficacy of ulcerative colitis [UC] treatments are lacking. Here, we performed a longitudinal study investigating the association and potential predictive power of genome-wide peripheral blood [PB] DNA methylation signatures and response to tofacitinib treatment in UC.

Methods

We recruited moderate-to-severe UC patients starting tofacitinib treatment, and measured PB DNA methylation profiles at baseline [T1], after 8 weeks [T2], and in a subset [n = 8] after a median of 20 weeks [T3] using the Illumina Infinium HumanMethylation EPIC BeadChip. After 8 weeks, we distinguished responders [R] from non-responders [NR] based on a centrally read endoscopic response [decrease in endoscopic Mayo score ≥1 or Ulcerative Colitis Endoscopic Index of Severity ≥2] combined with corticosteroid-free clinical and/or biochemical response. T1 PB samples were used for biomarker identification, and T2 and publicly available intraclass correlation [ICC] data were used for stability analyses. RNA-sequencing was performed to understand the downstream effects of the predictor CpG loci.

Results

In total, 16 R and 15 NR patients, with a median disease duration of 7 [4–12] years and overall comparable patient characteristics at baseline, were analysed. We identified a panel of 53 differentially methylated positions [DMPs] associated with response to tofacitinib [AUROC 0.74]. Most DMPs [77%] demonstrated both short- and long-term hyperstability [ICC ≥0.90], irrespective of inflammatory status. Gene expression analysis showed lower FGFR2 [pBH = 0.011] and LRPAP1 [pBH = 0.020], and higher OR2L13 [pBH = 0.016] expression at T1 in R compared with NR.

Conclusion

Our observations demonstrate the utility of genome-wide PB DNA methylation signatures to predict response to tofacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesColitis, UlcerativeDNA MethylationPyrimidinesHumansMaleFemaleAdultMiddle AgedLongitudinal StudiesSeverity of Illness IndexTreatment OutcomeProtein Kinase InhibitorsBiomarkers

Stichwörter der Autor:innen

Epigeneticsbiomarkerspersonalised medicine

Substanzen

tofacitinibPiperidinesPyrimidinesProtein Kinase InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Genome Diagnostics Laboratory, Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Horaizon, Bv, Delft, The Netherlands.

ORCID-Profile: Peter Lauffer

Förderung

  • Helmsley Foundation
  • Pfizer

Zitieren

APA

Joustra, V., Li Yim, A. Y. F., van Gennep, S., Hageman, I., de Waard, T., Levin, E., Lauffer, P., de Jonge, W., Henneman, P., Löwenberg, M., & D'Haens, G. (2024). Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis. Journal of Crohn's and Colitis, 18(8), 1179-1189. https://doi.org/10.1093/ecco-jcc/jjad129

Vancouver

Joustra V, Li Yim AYF, van Gennep S, Hageman I, de Waard T, Levin E, et al. Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis. Journal of Crohn's and Colitis. 2024;18(8):1179-1189. doi:10.1093/ecco-jcc/jjad129

BibTeX
@article{Joustra2024,
  author = {Joustra, Vincent and Li Yim, Andrew Y F and van Gennep, Sara and Hageman, Ishtu and de Waard, Tristan and Levin, Evgeni and Lauffer, Peter and de Jonge, Wouter and Henneman, Peter and Löwenberg, Mark and D'Haens, Geert},
  title = {Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  volume = {18},
  number = {8},
  pages = {1179--1189},
  doi = {10.1093/ecco-jcc/jjad129}
}
Kostenlos starten →